Bristol-Myers Squibb Company (BMY) stock faces potential risks due to proposed updates concerning Medicare drug price negotiations.

An analysis examining whether Bristol-Myers Squibb stock is underperforming compared to the Dow Jones Industrial Average.

Bristol-Myers Squibb (BMY) is being evaluated as one of the best dividend stocks for investment, according to analysis of hedge fund holdings. The article explores its potential as a reliable income-generating asset.

Bristol-Myers Squibb is integrating Anthropic's Claude AI across its operations, making it available to 30,000 employees. This move aims to enhance productivity and innovation within the company.

A new analyst report has been published providing insights and analysis on the pharmaceutical company Bristol-Myers Squibb Co.

The anticoagulant drug Eliquis, a product of Bristol-Myers Squibb and Pfizer, is slated to become available through Mark Cuban's Cost Plus Drug Company.

A new analyst report provides insights and analysis on the pharmaceutical company Bristol-Myers Squibb Co.

The Ariel Global Fund has re-added Bristol-Myers Squibb Company (BMY) to its portfolio, citing the company's strong pipeline and attractive valuation as key factors.

Pharmaceutical giant Bristol-Myers Squibb (BMY) is experiencing mixed analyst sentiment, with Jim Cramer specifically highlighting recent stock pullbacks as excellent buying opportunities despite broader industry momentum.

UBS has increased its price target for Bristol-Myers Squibb (BMY) as the market anticipates upcoming data for its drug Milvexian.

Wall Street analysts are providing their insights and opinions on Bristol-Myers Squibb Company (BMY).

Bristol-Myers Squibb Company and SystImmune have released the results from their analyses of Iza-bren studies. The announcement provides new data regarding the ongoing research.

Bristol-Myers Squibb's latest data on multiple myeloma has reportedly provided a boost to C4 Therapeutics, indicating a positive market reaction to the research findings.

Bristol-Myers Squibb stock saw a rise following news of a deal with Anthropic AI, which analysts suggest could be a key upside catalyst for the company.

Bristol-Myers Squibb Company (BMY) has reported quarterly profits that surpassed analyst estimates.

Analysts on Wall Street are currently assessing and providing their opinions on the investment prospects of Bristol-Myers Squibb stock.

Bristol-Myers Squibb Company (BMY) has been identified as a favorable stock choice for investors with conservative portfolios, according to recent financial analysis.

A market digest provides an overview of activity related to stocks BMY (Bristol-Myers Squibb) and SWX.

Bristol-Myers Squibb has obtained FDA approval for a new treatment targeting Hodgkin’s Lymphoma.

An analysis suggests Bristol-Myers Squibb is a reliable dividend stock suitable for long-term holding, even through market downturns.

Bristol-Myers Squibb Company has announced a dividend of $0.63 per share.

Several companies and ETFs, including Equity Residential, SL Green Realty, and various Purpose and Evolve funds, have announced their latest dividend declarations. These declarations range from cash dividends to monthly distributions across different investment vehicles.

Pharmaceutical giant Bristol-Myers Squibb has announced a partnership with AI safety and research company Anthropic.

Bristol-Myers Squibb and Palantir Technologies both experienced declines in their stock prices. This drop followed a period of six consecutive sessions of gains for both companies.

Bristol-Myers Squibb's stock experienced a decline for the seventh consecutive trading session.

Bristol-Myers Squibb's significant $14 billion investment in a neuroscience drug has reportedly turned into an early letdown, indicating potential setbacks for the pharmaceutical giant's venture.

An analysis assesses whether Bristol-Myers Squibb Company (BMY) is currently a good stock to purchase for investors.

Piper Sandler analysts foresee a path to growth for Bristol-Myers Squibb Company (BMY) following the expiry of its Eliquis patent, suggesting new opportunities for the pharmaceutical firm.